News Column

Bactiguard prices its initial public offering at SEK 38 per B share – trading commences on NASDAQ OMX Stockholm today

June 18, 2014



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECLTY, IN USA, AUSTRALIA, CANADA, HONG KONG OR JAPAN.

Bactiguard Holding AB (publ) (“Bactiguard” or “The Company”) hereby announces the outcome of the offer to acquire shares in Bactiguard and listing on NASDAQ OMX Stockholm (“the Offer”).

Interest in the Offer has been substantial, both among Swedish and international investors and among the public in Sweden. The Offer was oversubscribed, and trading in the Company's shares on NASDAQ OMX Stockholm starts today.

Outcome of the Offer in brief:

· The final price of the Offer has been set at SEK 38 per B share

· The outcome of the Offer comprises a total of 10,922,244 B shares, of which 6,305,573 newly-issued B shares and 4,616,671 existing B shares

· An additional 1,638,336 B shares may be sold by the Company's principal owners, Thomas von Koch through Bactiguard B.V. and Christian Kinch through KK Invest AB, to cover the over-allocation (”The Over-Allocation Option”)[1] (http://file///C:/Users/ced/Desktop/Bactiguard%20prices%20its %20initial%20public%20offering%202014-06-19.docx#_ftn1)

· The listing concludes the offset offer to bond holders in the Company. In total, bonds equivalent to a nominal value of SEK 222.5 million are being set-off to B shares

· The total value of the Offer amounts to approximately SEK 415 million (approximately SEK 477 million if The Over-Allocation Option is exercised to its full extent), of which approximately SEK 240 million is injected as issue proceeds to The Company for the newly issued B shares (before issue costs) and approximately SEK 175 million is related to B shares which have been sold by bond holders that have chosen to convert their bonds into B shares in the set-off issue

· The principal owners have decided to reduce the number of existing shares in the offer, which decreases the Offer by approximately SEK 216 million from what has previously been communicated

· Following the Offer, the total number of B shares in Bactiguard amounts to 29,302,373 and the total number of A shares to 4,000,000

· Based on the final price of the Offer, the value of all Bactiguard's shares amounts to approximately SEK 1,265 million

· The shares have been allocated to international and Swedish institutional investors and to the public in Sweden

· Following the Offer, Bactiguard will have approximately 2,700 shareholders

· Trading in the Bactiguard share on NASDAQ OMX Stockholm will commence today, 19 June 2014, under ticker symbol "BACTI"[2] (http://file///C:/Users/ced/Desktop/Bactiguard%20prices%20its% 20initial%20public%20offering%202014-06-19.docx#_ftn2)

Quote from Johan Rugfelt, CEO of Bactiguard:

”Bactiguard’s mission is to prevent healthcare-related infections, reduce the use of antibiotics and save lives by developing and manufacturing infection preventive healthcare products. In recent years we have concentrated on developing our own product portfolio and building up a global network of distributors. With the listing of Bactiguard, the final piece of the puzzle falls into place as this provides us with the financial strength necessary to genuinely realise the vigorous growth that we see ahead of us.”

Quote from Christian Kinch, Chairman of Bactiguard’s board of directors and principal owner:

”Bactiguard's journey so far has been fantastic, from technical innovation and a licensing business to an international medtech company with its own product portfolio. During the subscription period we have experienced great interest in Bactiguard, from both the public and institutions, and it is gratifying that the offer has been oversubscribed. However, we have received requests from many investors that we, as principal owners, should retain a larger shareholding than was initially deemed appropriate. We have therefore decided to reduce the number of existing shares being sold. We see great potential in Bactiguard, and we look forward to participating in the company's continued development and value growth together with new shareholders.”

Swedbank has acted as Lead Manager and Sole Bookrunner and ABG Sundal Collier has acted as Co-Lead Manager in connection with the IPO. Cederquist is legal advisor and Lenner & Partners is financial advisor to the Company.

This is information that Bactiguard Holding AB (publ) is required to publish in compliance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on 19 June 2014, at 07.00.

----------

[1] (http://file///C:/Users/ced/Desktop/Bactiguard%20prices%20its%20initi al%20public%20offering%202014-06-19.docx#_ftnref1) The over-allocation option can be exercised, on one or more occasions, entirely or in part, by the Lead Manager as the stabilising manager, during a period of 30 days from the first day of trading in the Company's B shares on NASDAQ OMX Stockholm.

[2] (http://file///C:/Users/ced/Desktop/Bactiguard%20prices%20its%20initi al%20public%20offering%202014-06-19.docx#_ftnref2) Trade in the Bactiguard share on NASDAQ OMX Stockholm until 25 June 2014 is conditional upon fulfilment of the terms of the offer. For further information, please contact:

Johan Rugfelt - CEO johan.rugfelt@bactiguard.se +46 708 724 739

Fredrik JÄrrsten - CFO fredrik.jarrsten@bactiguard.se +46 72 550 00 89

Cecilia EdstrÖm - Director of Communications cecilia.edstrom@bactiguard.se +46 722 262 328 Bactiguard Bactiguard is a Swedish medtech company with a mission of preventing healthcare associated infections, reducing the use of antibiotics and saving lives by developing and supplying infection prevention solutions to the healthcare industry. The company’s patented coating prevents healthcare associated infections by reducing bacterial adhesion and growth on medical devices. Bactiguard®-coated urinary catheters are market leading in the US and Japan, and in recent years the company has developed its own product portfolio of coated catheters for the urinary and respiratory tract and the blood stream. Bactiguard is currently in a strong expansion phase, focused on new markets in the EU, Middle East, Asia and South America. The company reported  sales of approximately SEK 130 million in 2013, has 60 employees, headquarters in Stockholm and production facilities in Markaryd and Malaysia.



This information was brought to you by Cision http://news.cision.com

http://news.cision.com/bactiguard-holding-ab--publ-/r/bactiguard-prices-its-initial-public-offering-at-sek-38-per-b-share---trading-commences-on-nasdaq-om,c9604657

The following files are available for download:

http://mb.cision.com/Main/9686/9604657/258538.pdf


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Cision


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters